As of 30 September 2022, the total number of shares and votes in IRRAS AB (“IRRAS”) amounts to 794,813,400.
The number of shares and votes in IRRAS has increased as a result of the registration of 230,572,566 ordinary shares subscribed for without the support of subscription rights, which in accordance with previously announced information, was issued in connection with the rights issue that was resolved by the board of directors on 4 July 2022 and approved by the extraordinary general meeting held on 3 August 2022.
This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980). This press release was made public, through the agency of the person below on 30 September 2022, at 08.00 a.m. CEST.
IRRAS is a global medical care company focused on innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
Director, Investor Relations
+46 102 11 5172